DR. REDDY'S LABORATORIES-ADR (RDY) Stock Price & Overview
NYSE:RDY • US2561352038
The current stock price of RDY is 14.4 USD. Today RDY is up by 0.91%. In the past month the price increased by 3.08%. In the past year, price increased by 11.54%.
RDY Key Statistics
- Market Cap
- 11.989B
- P/E
- 19.73
- Fwd P/E
- 23.08
- EPS (TTM)
- 0.73
- Dividend Yield
- 0.61%
RDY Stock Performance
RDY Stock Chart
RDY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RDY. When comparing the yearly performance of all stocks, RDY turns out to be only a medium performer in the overall market: it outperformed 60.56% of all stocks.
RDY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RDY. RDY scores excellent on profitability, but there are some minor concerns on its financial health.
RDY Earnings
On January 21, 2026 RDY reported an EPS of 14.53 and a revenue of 87.53B. The company beat EPS expectations (4.69% surprise) and beat revenue expectations (2.4% surprise).
RDY Forecast & Estimates
44 analysts have analysed RDY and the average price target is 15.24 USD. This implies a price increase of 5.82% is expected in the next year compared to the current price of 14.4.
For the next year, analysts expect an EPS growth of -6.34% and a revenue growth 6.48% for RDY
RDY Groups
Sector & Classification
RDY Financial Highlights
Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.73. The EPS increased by 3.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| Debt/Equity | 0.03 |
RDY Ownership
RDY Latest News, Press Relases and Analysis
RDY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.51 | 929.554B | ||
| JNJ | JOHNSON & JOHNSON | 20.63 | 577.341B | ||
| MRK | MERCK & CO. INC. | 21.4 | 288.088B | ||
| PFE | PFIZER INC | 9.01 | 151.297B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 123.651B | ||
| ZTS | ZOETIS INC | 17.68 | 53.866B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.368B | ||
| VTRS | VIATRIS INC | 5.64 | 16.73B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.21 | 11.892B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.259B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.474B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.46B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RDY
Company Profile
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Company Info
DR. REDDY'S LABORATORIES-ADR
8-2-337, Road No.3 Banjara Hills
Hyderabad TELANGANA 500-034 IN
CEO: Erez Israeli
Employees: 26944
Phone: 914049002900
DR. REDDY'S LABORATORIES-ADR / RDY FAQ
What does DR. REDDY'S LABORATORIES-ADR do?
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
What is the stock price of DR. REDDY'S LABORATORIES-ADR today?
The current stock price of RDY is 14.4 USD. The price increased by 0.91% in the last trading session.
Does RDY stock pay dividends?
DR. REDDY'S LABORATORIES-ADR (RDY) has a dividend yield of 0.61%. The yearly dividend amount is currently 0.09.
How is the ChartMill rating for DR. REDDY'S LABORATORIES-ADR?
RDY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for RDY stock?
The PE ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 19.73. This is based on the reported non-GAAP earnings per share of 0.73 and the current share price of 14.4 USD.
Can you provide the upcoming earnings date for DR. REDDY'S LABORATORIES-ADR?
DR. REDDY'S LABORATORIES-ADR (RDY) will report earnings on 2026-05-07, after the market close.
What is the outstanding short interest for DR. REDDY'S LABORATORIES-ADR?
The outstanding short interest for DR. REDDY'S LABORATORIES-ADR (RDY) is 2.18% of its float.